Cipla share price down more than 2%: should you BUY, Sell or Hold the stock post Q3 earnings ?

livemint.com:

Cipla share price declined more than 3% in the morning trades on Monday. It was amongst the largest losers in the Nifty-50 stocks on a day when benchmark indices gained around 0.8%. Cipla had reported a resilient performance in the December quarter last week, that was supported by strong growth in both India and the US markets.

India sales at ₹2,859 Crore contributing more than 40% to overall revenues grew 11.6% y-o-y. North American sales at ₹1,916, contributing almost 30% to overall revenues also grew 19.8% y-o-y. It was the highest ever quarter at $ 230 million at 18% YoY growth supported by continuing momentum in key assets and robust demand in base business along with some year-end buying.

This meant that overall revenues for Cipla at ₹6,544 crore could grow 14.2% y-o-y. Its Earnings before interest tax depreciation and amortisations (Ebitda) at ₹1,720 crore grew 24.9% y-o-y. The Ebitda margins at 26.3% expanded 230 bps while reported net profit at ₹1,049 crore also grew 32.7% y-o-y.

Know what Brokerages are saying- HSBC Securities and Capital Markets (India) Private Ltd have retained Buy ratings on Cipla and raised their target price to ₹ ₹1,500 (from ₹1,485). They say that the traction in lanreotide 505b2, generics of Revlimid and launches to help US sales. Lanreotide is a drug used for management of acromegaly and symptoms caused by neuroendocrine tumors, Revlimid is a multiple Myeloma treatment drug.